Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies.

Gladman DD, Kavanaugh A, Gómez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, Lespessailles E, Guerette B, Delev N, Teng L, Edwards CJ, Birbara CA, Mease PJ.

RMD Open. 2018 Jun 27;4(1):e000669. doi: 10.1136/rmdopen-2018-000669. eCollection 2018.

2.

Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis.

Gottlieb AB, Papp KA, Birbara CA, Shuler CL, Burge R, Erickson J, Kerr L, Mease PJ.

J Am Acad Dermatol. 2018 Sep;79(3):593-595. doi: 10.1016/j.jaad.2018.03.008. Epub 2018 Mar 17. No abstract available.

PMID:
29559395
3.

Safety and efficacy of subcutaneous tanezumab in patients with knee or hip osteoarthritis.

Birbara C, Dabezies EJ Jr, Burr AM, Fountaine RJ, Smith MD, Brown MT, West CR, Arends RH, Verburg KM.

J Pain Res. 2018 Jan 8;11:151-164. doi: 10.2147/JPR.S135257. eCollection 2018.

4.

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).

Edwards CJ, Blanco FJ, Crowley J, Birbara CA, Jaworski J, Aelion J, Stevens RM, Vessey A, Zhan X, Bird P.

Ann Rheum Dis. 2016 Jun;75(6):1065-73. doi: 10.1136/annrheumdis-2015-207963. Epub 2016 Jan 20.

5.

Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy.

Furst DE, Kavanaugh A, Florentinus S, Kupper H, Karunaratne M, Birbara CA.

Rheumatology (Oxford). 2015 Dec;54(12):2188-97. doi: 10.1093/rheumatology/kev249. Epub 2015 Jul 21.

PMID:
26199453
6.

Effects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: results of a phase 1, randomized, open-label trial.

Doyle MK, Rahman MU, Frederick B, Birbara CA, de Vries D, Toedter G, Wu X, Chen D, Ranganath VK, Westerman ME, Furst DE.

Rheumatology (Oxford). 2013 Jul;52(7):1214-9. doi: 10.1093/rheumatology/kes381. Epub 2013 Feb 14.

PMID:
23418046
7.

Intra-articular hylastan versus steroid for knee osteoarthritis.

Housman L, Arden N, Schnitzer TJ, Birbara C, Conrozier T, Skrepnik N, Wei N, Bockow B, Waddell D, Tahir H, Hammond A, Goupille P, Sanson BJ, Elkins C, Bailleul F.

Knee Surg Sports Traumatol Arthrosc. 2014 Jul;22(7):1684-92. doi: 10.1007/s00167-013-2438-7. Epub 2013 Feb 16.

PMID:
23417236
8.

Efficacy and safety of tanezumab in the treatment of chronic low back pain.

Katz N, Borenstein DG, Birbara C, Bramson C, Nemeth MA, Smith MD, Brown MT.

Pain. 2011 Oct;152(10):2248-58. doi: 10.1016/j.pain.2011.05.003. Epub 2011 Jun 21.

PMID:
21696889
9.

Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain.

Schnitzer TJ, Lane NE, Birbara C, Smith MD, Simpson SL, Brown MT.

Osteoarthritis Cartilage. 2011 Jun;19(6):639-46. doi: 10.1016/j.joca.2011.01.009. Epub 2011 Jan 18.

10.

Tanezumab for the treatment of pain from osteoarthritis of the knee.

Lane NE, Schnitzer TJ, Birbara CA, Mokhtarani M, Shelton DL, Smith MD, Brown MT.

N Engl J Med. 2010 Oct 14;363(16):1521-31. doi: 10.1056/NEJMoa0901510. Epub 2010 Sep 29.

11.

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT).

Mease PJ, Ory P, Sharp JT, Ritchlin CT, Van den Bosch F, Wellborne F, Birbara C, Thomson GT, Perdok RJ, Medich J, Wong RL, Gladman DD.

Ann Rheum Dis. 2009 May;68(5):702-9. doi: 10.1136/ard.2008.092767. Epub 2008 Aug 6.

12.

Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2.

van der Heijde D, Kavanaugh A, Gladman DD, Antoni C, Krueger GG, Guzzo C, Zhou B, Dooley LT, de Vlam K, Geusens P, Birbara C, Halter D, Beutler A.

Arthritis Rheum. 2007 Aug;56(8):2698-707.

13.
14.

Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial.

Kavanaugh A, Krueger GG, Beutler A, Guzzo C, Zhou B, Dooley LT, Mease PJ, Gladman DD, de Vlam K, Geusens PP, Birbara C, Halter DG, Antoni C; IMPACT 2 Study Group.

Ann Rheum Dis. 2007 Apr;66(4):498-505. Epub 2006 Nov 17.

15.

Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life.

Emery P, Kosinski M, Li T, Martin M, Williams GR, Becker JC, Blaisdell B, Ware JE Jr, Birbara C, Russell AS.

J Rheumatol. 2006 Apr;33(4):681-9. Epub 2006 Mar 1.

PMID:
16568505
16.

Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies.

Birbara C, Ruoff G, Sheldon E, Valenzuela C, Rodgers A, Petruschke RA, Chang DJ, Tershakovec AM.

Curr Med Res Opin. 2006 Jan;22(1):199-210.

PMID:
16393445
17.

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.

Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C, Box J, Natarajan K, Nuamah I, Li T, Aranda R, Hagerty DT, Dougados M.

N Engl J Med. 2005 Sep 15;353(11):1114-23. Erratum in: N Engl J Med. 2005 Nov 24;353(21):2311.

18.

Frequency, predictors, and economic impact of upward dose adjustment of infliximab in managed care patients with rheumatoid arthritis.

Ollendorf DA, Massarotti E, Birbara C, Burgess SM.

J Manag Care Pharm. 2005 Jun;11(5):383-93.

19.

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.

Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, Zhou B, Dooley LT, Kavanaugh A; IMPACT 2 Trial Investigators.

Ann Rheum Dis. 2005 Aug;64(8):1150-7. Epub 2005 Jan 27.

20.
21.

Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: improvement in pain and disability--a randomized, placebo-controlled, 3-month trial.

Birbara CA, Puopolo AD, Munoz DR, Sheldon EA, Mangione A, Bohidar NR, Geba GP; Etoricoxib Protocol 042 Study Group.

J Pain. 2003 Aug;4(6):307-15.

PMID:
14622687
22.

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.

Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK.

Arthritis Rheum. 2003 Jan;48(1):35-45. Erratum in: Arthritis Rheum. 2003 Mar;48(3):855.

23.

Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease. Rabeprazole Study Group.

Birbara C, Breiter J, Perdomo C, Hahne W.

Eur J Gastroenterol Hepatol. 2000 Aug;12(8):889-97.

PMID:
10958216
24.

Single infusion of zoledronate in Paget's disease of bone: a placebo-controlled, dose-ranging study.

Buckler H, Fraser W, Hosking D, Ryan W, Maricic MJ, Singer F, Davie M, Fogelman I, Birbara CA, Moses AM, Lyles K, Selby P, Richardson P, Seaman J, Zelenakas K, Siris E.

Bone. 1999 May;24(5 Suppl):81S-85S. No abstract available.

PMID:
10321935
26.

Reiter's syndrome.

Calabro JJ, Garg SL, Khoury MI, Long JA Jr, Birbara CA.

Am Fam Physician. 1974 Apr;9(4):80-94. No abstract available.

PMID:
4819042
27.

Meningococcal infections at an army training center.

Wolf RE, Birbara CA.

Am J Med. 1968 Feb;44(2):243-55. No abstract available.

PMID:
4965818

Supplemental Content

Loading ...
Support Center